Jeff Hansen

Jeff Hansen

| This email address is being protected from spambots. You need JavaScript enabled to view it.

Research Editor

jeffhans@uab.edu • (205) 209-2355

Communicates UAB research discoveries and initiatives from across the university for a variety of audiences.

Specific beats include: biochemistry; cell, developmental and integrated biology; microbiology; molecular genetics; neurobiology; pathology; pharmacology and tocixology; Alabama Drug Discovery Alliance; Bill L. Harbert Institute for Innovation and Entrepreneurship.

The complement system is part of the body’s immune system to fight pathogens and remove cell debris. Its role in two autoimmune diseases and a mental disorder is a surprise.
Dual antiplatelet therapy after percutaneous coronary intervention uses aspirin and one other drug, among several choices. But which drug is best to use?
This discovery may have clinical importance in management of heart failure.
A microbiome “fingerprint” method allows tracking of mothers’ microbial strains inherited by infants.
The research is led by an Oregon cancer research institute, in collaboration with two biotech companies and the National Institutes of Health.
The ranking measured 79 anatomy/cell biology departments in U.S. medical schools.
The work centers around ReFRAME, a vast collection of drugs developed for other diseases that are already known to be safe for humans.
The goal is material that approaches a diamond in hardness and can survive extreme pressure, temperature and corrosive environments.
This discovery has implications in cancer, stem cell growth, and blood or neuron progenitor cell speciation.
The testing at UAB will investigate immune responses to the vaccine in mice — an important step before any Phase 1 human safety trial in patients later this year.
Page 1 of 30